New York, June 4, 2026, 08:04 EDT
uniQure N.V. shares eased in pre-market trading Thursday, trimming part of Wednesday’s 11.7% jump as traders moved around the Dutch biotech’s uncertain Huntington’s disease gene therapy outlook. The stock ended at $29.88 in the prior session and changed hands at $29.40 ahead of the Nasdaq open at 8:00 a.m. EDT.
QURE now trades mostly as a play on AMT-130, its main program for Huntington’s disease. The disease is fatal and inherited. uniQure has been telling investors it plans to file for UK marketing authorization—a request to sell the drug—in the third quarter of 2026, and is also looking for more guidance from U.S. regulators.
Amsterdam-based uniQure (QURE) is valued around $1.9 billion based on the most recent Nasdaq price. The shares are still trading far from their 52-week peak, and the stock reacts sharply to any news from trials or regulators.
uniQure said April 30 that UK regulators had a pre-submission meeting on AMT-130. The company wants to file with three-year Phase I/II data. CEO Matt Kapusta described the MHRA’s feedback as “constructive” and said the planned filing is “an important milestone” for the Huntington’s disease community. GlobeNewswire
uniQure said in the same update it has a Type B meeting on the calendar with the U.S. Food and Drug Administration in the second quarter. Type B meetings are formal sit-downs, often used for hashing out trial designs or development plans. Here, uniQure expected to talk with the FDA about a potential Phase III study and how it plans to handle the four-year AMT-130 data set coming in the third quarter.
uniQure’s latest quarter put the focus on the regulatory timeline again. The company closed March 31 with $586.6 million in cash, cash equivalents and current investment securities and expects that to last into the second half of 2029. Revenue in the first quarter came in at $3.6 million. Net loss was $53.5 million, or 85 cents per share.
AMT-130 aims to cut levels of huntingtin, which drives Huntington’s disease. In September, uniQure said patients given a high dose of AMT-130 saw disease progression slow by 75% after 36 months, compared with an external control group. Sarah Tabrizi, professor of clinical neurology at University College London, said the results are “the most convincing in the field to date.” GlobeNewswire
But the trade is still on shaky ground. Back in March, Reuters said a senior FDA official called the therapy a “failed product” and argued against the company’s use of an external comparison group. uniQure responded that it was “confident in the strength of the data” and planned to talk with regulators. Investors know the risk: the FDA could demand a longer, randomized Phase III study before any filing in the U.S., pushing any revenue further out and bringing more financing risk. Reuters
The risk was already known. Back in November, Reuters said the FDA had stopped considering AMT-130 data as enough for an accelerated-approval biologics license application, which handles complex biologics in the U.S. Guggenheim’s Debjit Chattopadhyay at the time said the FDA likely saw the analysis as “post hoc.” Cantor Fitzgerald’s Kristen Kluska called the timeline for a possible filing unclear. Reuters
The race among Huntington’s drug developers is still on, with no treatment yet approved to slow the disease. PTC Therapeutics said its PTC518 study hit the main goal by cutting blood huntingtin protein. CEO Matthew Klein pointed to “early signals of clinical benefit.” Wave Life Sciences showed lowering of mutant huntingtin with WVE-003. Roche has a Phase II trial of tominersen testing the drug against placebo. PTC Therapeutics. Wave Life Sciences Roche
The stock is still caught between hopes and hard results. Looking ahead, regulatory updates are next, including feedback from the FDA meeting, the four-year AMT-130 data, and if the UK filing plans stay on track.
